Target type: biologicalprocess
The movement of a mononuclear cell within or between different tissues and organs of the body. [GOC:mah]
Mononuclear cell migration is a complex process involving a coordinated interplay of multiple factors, including chemotaxis, chemokinesis, and adhesion. Mononuclear cells, such as lymphocytes, monocytes, and macrophages, are essential components of the immune system, and their migration is crucial for immune surveillance, inflammation, and wound healing.
**Chemotaxis:** This is the directed movement of cells along a chemical gradient. Mononuclear cells possess receptors that recognize and bind to specific chemoattractant molecules, which are secreted by cells at the site of inflammation or infection. These chemoattractants include chemokines, cytokines, and complement components. Binding of chemoattractants to their receptors triggers intracellular signaling pathways that activate the cell's cytoskeleton and motility machinery, leading to directed movement towards the source of the chemoattractant.
**Chemokinesis:** This is the random movement of cells in response to a non-directional chemical stimulus. Chemokinesis can enhance the overall migration of mononuclear cells by increasing their motility and facilitating their exploration of the surrounding environment.
**Adhesion:** Mononuclear cells adhere to the extracellular matrix (ECM) and other cells through cell adhesion molecules (CAMs). These interactions provide a stable anchor for the cells, allowing them to exert force on the ECM and move through the tissues. The expression of CAMs on mononuclear cells is regulated by various factors, including chemokines, cytokines, and ECM components.
**Steps in Mononuclear Cell Migration:**
1. **Chemoattractant Recognition and Signal Transduction:** Mononuclear cells detect chemoattractant molecules through specific receptors on their cell surface. This recognition triggers intracellular signaling pathways that activate downstream effector molecules.
2. **Cytoskeletal Rearrangement:** Activated signaling pathways lead to changes in the cytoskeleton, particularly the polymerization of actin filaments. This polymerization forms protrusions called lamellipodia and filopodia, which extend towards the source of the chemoattractant.
3. **Adhesion and Detachment:** Mononuclear cells adhere to the ECM and other cells through CAMs. These interactions provide traction for the cells to move forward. As the cells move, they detach from the ECM and re-adhere to new sites, ensuring continuous migration.
4. **Cell Polarization:** Mononuclear cells become polarized during migration, with the leading edge facing the direction of movement. This polarization is driven by the accumulation of signaling molecules and cytoskeletal components at the leading edge.
5. **Cell Movement:** The coordinated actions of cytoskeletal rearrangements, adhesion, and detachment drive the cell's movement. The leading edge extends towards the chemoattractant, while the trailing edge detaches from the ECM and retracts.
**Regulation of Mononuclear Cell Migration:**
Mononuclear cell migration is tightly regulated by a complex network of signaling pathways, chemokines, cytokines, and ECM components. The regulation of these factors ensures that mononuclear cells migrate in a controlled and directed manner, reaching their intended destinations.
**Consequences of Aberrant Mononuclear Cell Migration:**
Dysregulation of mononuclear cell migration can contribute to various diseases, including autoimmune disorders, chronic inflammation, and cancer. For instance, excessive migration of immune cells into tissues can contribute to inflammatory damage, while deficient migration can impair immune responses to infections.
**Conclusion:**
Mononuclear cell migration is a vital process for immune surveillance, inflammation, and wound healing. This complex process involves a coordinated interplay of chemotaxis, chemokinesis, and adhesion. Understanding the molecular mechanisms that govern mononuclear cell migration is crucial for developing novel therapeutic strategies for various diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Galectin-3 | A galectin-3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P17931] | Homo sapiens (human) |
Plasminogen | A plasminogen that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00747] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
aminocaproic acid | 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator. Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. | amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid | antifibrinolytic drug; hematologic agent; metabolite |
5-(n,n-hexamethylene)amiloride | 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity | aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines | antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker |
bis(5-amidino-2-benzimidazolyl)methane | bis(5-amidino-2-benzimidazolyl)methane: aromatic diamidine which has a significant suppressive effect on the cytopathology & yield of respiratory synctial (RS) virus; RN given refers to parent cpd | ||
gabexate | Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin. | benzoate ester | |
nafamostat | nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic | benzoic acids; guanidines | |
netropsin | Netropsin: A basic polypeptide isolated from Streptomyces netropsis. It is cytotoxic and its strong, specific binding to A-T areas of DNA is useful to genetics research. | ||
pentamidine | pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic |
tranexamic acid | Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage. | amino acid | |
lactose | beta-lactose : The beta-anomer of lactose. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form. Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. | lactose | |
phenylguanidine | phenylguanidine: RN given refers to parent cpd | ||
amiloride | amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | aromatic amine; guanidines; organochlorine compound; pyrazines | diuretic; sodium channel blocker |
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
methyl alpha-d-galactopyranoside | methyl alpha-D-galactoside : An alpha-D-galactoside having a methyl substituent at the anomeric position. methyl-galactopyranoside: structure in first source | alpha-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
mci 9038 | peptide | ||
methyl beta-galactoside | methyl beta-D-galactoside : A beta-D-galactopyranoside having a methyl substituent at the anomeric position. methyl beta-galactoside: RN given refers to (beta-D)-isomer methyl galactoside : A methyl glycoside in which the H of the OH group on C-1 of galactose is replaced by a methyl group. | beta-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
thiodigalactoside | thiodigalactoside: RN given refers to beta-D-galactopyranoside (D-Gal)-isomer | ||
methyl lactoside | beta-D-Gal-(1->4)-beta-D-Glc-OMe : A methyl glycoside comprising methyl beta-D-glucoside having an beta-D-galactosyl residue at the 4-position. | disaccharide derivative; methyl glycoside | |
dx 9065 | |||
efegatran | efegatran: RN & structure given in first source; RN given refers to parent cpd (D)-isomer | ||
5-amidinoindole | |||
5-(4-piperidyl)isoxazol-3-ol | 5-(4-piperidyl)isoxazol-3-ol: structure given in first source; a partial agonist at the GABA-A receptor on cultured hippocampal neurones; antagonizes muscimol-stimulated benzodiazepine binding to rat cortical membranes | piperidines | |
ono 3307 | ONO 3307: RN given refers to parent cpd; structure given in first source | ||
4-guanidinobenzoate | 4-guanidinobenzoate: RN given refers to parent cpd 4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group. | benzoic acids; guanidines | |
melagatran | azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound | anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor | |
pefabloc | |||
beta-naphthamidine | beta-naphthamidine: RN given refers to parent cpd | ||
razaxaban | razaxaban: structure in first source | ||
dabigatran | dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. | aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines | anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor |
n-acetyllactosamine | N-acetyllactosamine : A beta-D-galactopyranosyl-(1->4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. N-acetyllactosamine: RN given refers to D-isomer | beta-D-Galp-(1->4)-D-GlcpNAc | |
galactose | alpha-D-galactoside : Any D-galactoside having alpha-configuration at its anomeric centre. | D-galactopyranose | mouse metabolite |
benzamidine | carboxamidinium ion | ||
galactal | galactal: RN given refers to cpd with unspecified isomeric designation; structure | anhydrohexose; glycal | |
2-(4-chlorophenyl)guanidine | organochlorine compound | ||
telaprevir | cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines | antiviral drug; hepatitis C protease inhibitor; peptidomimetic | |
3,7-dimethoxy-5,3',4'-trihydroxyflavone | 3,7-dimethoxy-5,3',4'-trihydroxyflavone: isolated from Veronia eremophila; structure given in first source 3',4',5-trihydroxy-3,7-dimethoxyflavone : A dimethoxyflavone that the 3,7-di-O-methyl derivative of quercetin. | dimethoxyflavone; trihydroxyflavone | EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite |
hydroxygenkwanin | hydroxygenkwanin: isolated from leaves of Daphne genkwa | ether; flavonoids | |
bms 740808 | 1-(3-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-6-(2'-(3-hydroxy-N-pyrrolidinyl)methyl-(1,1')-biphen-4-yl)-1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-one: structure in first source | ||
uk-356,202 | UK-356,202: structure in first source | ||
n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride | |||
gw 813893 | |||
lb 30057 | |||
a-317567 | A-317567: acid sensing ion channel blocker; structure in first source | ||
betrixaban | betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade. betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source | benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide | anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor |
rpr 120844 | |||
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | tripeptide; ureas | antiviral drug; hepatitis C protease inhibitor; peptidomimetic |
m-chlorophenylguanidine | |||
pf-2545920 | |||
mk-7009 | vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan. vaniprevir: inhibits hepatitis C virus NS3/4a protease | azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide | antiviral drug; hepatitis C protease inhibitor |
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
rpx7009 | RPX7009: a beta-lactamase inhibitor; structure in first source |